Neuroscientists face a paradox. The field aims to understand the mysteries of the human mind, but studying the actual human brain cells and circuits that produce our mental lives and how they go awry in neuropsychiatric disease is incredibly challenging. After all, the brain is packed away carefully in our skulls, and people typically don’t part with samples of their brain
Innovating to restore abilities lost to neurological damage stanford.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stanford.edu Daily Mail and Mail on Sunday newspapers.
New research in mice by scientists affiliated with the Wu Tsai Neurosciences Institute has shown how targeted stimulation of the brain’s serotonin system could improve memory for new acquaintances, even after a brief introduction.
UCSF and BridgeBio Pharma to Accelerate Therapies for Genetic Diseases
By Nicholas Weiler on December 22, 2020
SAN FRANCISCO – December 23, 2020 - UC San Francisco and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.
“The BridgeBio team is developing close relationships with our investigators at UCSF with the mission of bringing potential therapies into the clinic quickly, where they have the opportunity to help patients in need,” said Barry Selick, Ph.D., UCSF vice chancellor for business development, innovation and partnerships and director of the Office of Innovation Ventures. “We are excited about this partnership and the opportunities it may create for the development of new medicines.”
UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases BridgeBio Pharma, Inc.; UC San Francisco Palo Alto, California, UNITED STATES
SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.
“The BridgeBio team is developing close relationships with our investigators at UCSF with the mission of bringing potential therapies into the clinic quickly, where they have the opportunity to help patients in need,” said Barry Selick, Ph.D., UCSF vice chancellor for business development, innovation and partnerships and director of the Office of Innovation Ventures. “We are excited about this partnership and the opportunities it may create for the development of new medicines.”